The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Investigating combination therapies in LR-MDS
No combination therapies are currently approved for the treatment of lower-risk myelodysplastic syndrome (LR-MDS); however, they may hold the potential to improve patients’ outcomes in the future. Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, briefly outlines some of the combination therapy approaches being studied in this patient population. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Novartis, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Amgen, Curis, Geron, Silence Therapeutics, Takeda
Honoraria: Novartis, Jazz, Bristol Myers Squibb, Servier, Syros, Celgene, Silence Therapeutics, Takeda
Research Funding: Novartis, Roche, BeiGene, Jazz, Bristol Myers Squibb, Servier, Janssen Biotech, Syros, Merck, Fibrogen, Amgen, Curis, Geron, BMS, Silence Therapeutics, Takeda
Board of Directors/Advisory Committee: MDS Foundation, Bristol Myers Squibb
Travel Support: Bristol Myers Squibb
Medical Writing Support: Bristol Myers Squibb
